Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Cancer

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2016.03.006PMID 27062316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches

  2015cited by this paper
• Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration

  2015cited by this paper
• Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.

  2014cited by this paper
• Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients

  2014cited by this paper
• Updated UK Recommendations for HER2 assessment in breast cancer

  2014cited by this paper
• MiR‐489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway

  2014cited by this paper
• Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

  2013cited by this paper
• Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.

  2013cited by this paper
• Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.

  2013cited by this paper
• Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.

  2013cited by this paper
• Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.

  2013cited by this paper
• The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example

  2012cited by this paper
• Neoadjuvant treatment of breast cancer.

  2012cited by this paper
• Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

  2012cited by this paper
• A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

  2012cited by this paper
• HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods

  2011cited by this paper
• Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer

  2009cited by this paper
• Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

  2009cited by this paper
• The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast Carcinoma

  2008cited by this paper
• Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.

  2008cited by this paper
• Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.

  2007cited by this paper
• Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

  2006cited by this paper
• Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

  2004cited by this paper
• Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

  2004cited by this paper
• Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.

  2003cited by this paper
• HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

  2002cited by this paper
• Typing breast cancer following primary chemotherapy

  1999cited by this paper
• Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours.

  1996cited by this paper
• Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.

  1996cited by this paper
• Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?

  1990cited by this paper
• Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells.

  1990cited by this paper

• The utilization of CEUS and SWE for predicting pathological complete response to neoadjuvant chemotherapy for invasive breast cancer

  2026cites this paper
• Diagnostic pitfalls in needle core biopsy of the breast: an update

  2025cites this paper
• Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patients.

  2025cites this paper
• Histological types of invasive breast cancer in 830,000 women diagnosed in England during 1988–2016

  2025cites this paper
• Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study.

  2025cites this paper
• Mechanisms of reduced efficacy of HER2-targeted therapy in HER2-low breast cancer by long-term nicotine exposure in patient-derived xenograft mouse tumor models.

  2025cites this paper
• Immunohistochemical Changes After Neoadjuvant Chemotherapy and Their Impact on Breast Cancer Survival: A Systematic Review and Meta-analysis.

  2025cites this paper
• Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study

  2024cites this paper
• Evaluating Biomarker Dynamics in Breast Cancer Post-Neoadjuvant Chemotherapy: A Retrospective Cross-sectional Study

  2024cites this paper
• A study of the assessment of pathological response to neoadjuvant chemotherapy in patients with breast cancer

  2024cites this paper
• Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers

  2024cites this paper
• Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study

  2024cites this paper
• The combination of breast cancer PDO and mini‐PDX platform for drug screening and individualized treatment

  2024cites this paper
• Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients.

  2023cites this paper
• Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment

  2023cites this paper
• Change in Main Histological Type of Invasive Breast Cancer From Ductal to Lobular Carcinoma by Neoadjuvant Chemotherapy

  2023influential citation
• Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy

  2023cites this paper
• Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy

  2023cites this paper
• Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

  2023cites this paper
• Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy

  2023cites this paper
• Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological Parameters and Molecular Imaging

  2023cites this paper
• Neoadjuvant Therapy in Breast Cancer: Histologic Changes and Clinical Implications.

  2022cites this paper
• Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer

  2022cites this paper
• Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy

  2022cites this paper
• Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.

  2022cites this paper
• Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer

  2022cites this paper
• Molecular Characterization of Exosomes for Subtype-Based Diagnosis of Breast Cancer.

  2022cites this paper
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications

  2022cites this paper
• HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review

  2022cites this paper
• Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

  2021cites this paper
• Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer

  2021cites this paper
• Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

  2021cites this paper
• Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer

  2021cites this paper
• HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features

  2021cites this paper
• Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy

  2021cites this paper
• Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy.

  2021cites this paper
• Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis

  2021cites this paper
• Diagnostic pitfalls in needle core biopsy of the breast

  2021cites this paper
• University of Birmingham Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer

  2021cites this paper
• Applying the New Guidelines of HER2 Testing in Breast Cancer

  2020cites this paper
• The Potential Usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice

  2020cites this paper
• Molecular phenotype discordance between primary and synchronous metastatic lesions of breast cancer and its determinant role in guiding treatment decisions: a case report.

  2020cites this paper
• Effect of neoadjuvant therapy on breast cancer biomarker profile

  2020cites this paper
• Hormone Receptors in Breast Cancer

  2019cites this paper
• Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer

  2019cites this paper
• Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy

  2019cites this paper
• Impact of Neoadjuvant Chemotherapy on Breast Cancer Biomarkers: A Guide for Further Adjuvant Treatment

  2019cites this paper
• Study characteristics affecting the responses to neoadjuvant chemotherapy and the prognosis of patients with bilateral breast cancer: A retrospective analysis

  2019influential citation
• Loss of HER2 after HER2-targeted treatment

  2019cites this paper
• Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material

  2019cites this paper
• The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches

  2019cites this paper
• Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma

  2019influential citation
• HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation

  2019cites this paper
• Effects of core needle biopsy and subsequent neoadjuvant chemotherapy on molecular alterations and outcome in breast cancer

  2018cites this paper
• Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer

  2018cites this paper
• Diagnostic value of ultrasound combined with magnetic resonance imaging in different stages of breast cancer

  2018cites this paper
• Novel mechanisms of HER2-targeted therapy resistance in breast cancer

  2018cites this paper
• Clinical Value of the Changes of ER, PR, HER2 and Ki-67 Expressions Before and After Neoadjuvant Chemotherapy in Breast Cancer

  2018cites this paper
• Correlation between the dynamic contrast-enhanced MRI features and prognostic factors in breast cancer

  2018cites this paper
• Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.

  2017cites this paper
• Drug-biomarker co-development in oncology - 20 years and counting.

  2017cites this paper
• Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.

  2017cites this paper
• Introduction Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer

  2017cites this paper
• Organochlorine pesticides accumulation and breast cancer: A hospital-based case–control study

  2017cites this paper
• Comparison of strain and shear-wave ultrasounic elastography in predicting the pathological response to neoadjuvant chemotherapy in breast cancers

  2017cites this paper
• Breast Cancer Biomarker Changes after Neoadjuvant Chemotherapy: A Single Institution Experience and Literature Review

  2017cites this paper
• High expression of COX5B is associated with poor prognosis in breast cancer.

  2017cites this paper
• The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy

  2016cites this paper
• Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

  2016cites this paper
• Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?

  2016cites this paper
• Neoadjuvante Chemotherapie beeinflusst das Tumorprofil bei Brustkrebs?

  2016cites this paper
• University of Birmingham Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy

  year unknowncites this paper